🌅 Pre-Market Pulse
|
S&P Futures
7,555.25
▲ +11.25 (+0.15%)
|
Nasdaq Futures
29,598.00
▲ +174.50 (+0.59%)
|
Dow Futures
52,572.00
▼ -25.00 (-0.05%)
|
|
10Y Treasury
4.61%
▲ +0.04%
|
US Dollar
101.16
▼ -0.02 (-0.02%)
|
Bitcoin
$62,670
▲ +$405 (+0.65%)
|
👀 What to Watch Today
Today's session will be driven more by corporate news flow than scheduled economic data, which puts the spotlight squarely on individual stock stories. The AstraZeneca (AZN) licensing deal for lung cancer drug Zegfrovy, worth up to $1.5 billion, and the Spero-Innovent Biologics (IVBIY) autoimmune deal worth up to $1.1 billion are the kind of headline-grabbing moves that tend to lift the broader biotech and pharma space.On the regulatory front, Google (GOOG, GOOGL) is now facing scrutiny from Switzerland's Competition Commission over its Android default search practices. That's another entry in the growing global antitrust file against Alphabet, and traders will want to see how that pressures the stock heading into today's open.
Keep an eye on Treasury yields as well. The 10-year is sitting at 4.61% and the 30-year is at 5.10%, both creeping higher overnight. Rising yields have a way of dampening enthusiasm for growth and tech names, so the relationship between Nasdaq futures strength and bond market pressure is worth monitoring closely through the session.
🌏 Overnight Recap
Overnight, the big headline out of Asia was Samsung's (SSNLF) reported exploration of a U.S. ADR listing, per Bloomberg. That's a significant signal for one of the world's largest chipmakers and could open the door to broader U.S. retail and institutional access to Samsung shares. The story is early-stage, but it's generating real buzz in overnight trading.On the geopolitical energy front, Iran's oil minister confirmed via Telegram that the country's oil exports are continuing despite the U.S. canceling a 60-day sanctions waiver last week. That's a story worth tracking for its potential impact on crude prices and energy equities as the session unfolds.
Meanwhile, Shein officially received Chinese regulatory approval for its long-awaited Hong Kong IPO, targeting a $40 billion valuation. That's a major development for the fast-fashion sector and signals renewed appetite for large-scale consumer tech listings out of China, even as the company navigates ongoing Western regulatory headwinds.
Louis Navellier: "This Could Be Bigger Than Nvidia"
Popular Fox News guest Louis Navellier sat down for a tell-all interview on Elon Musk's little-known AI project in Tennessee. He reveals why competitors are flying spy planes overhead… and details three little-known stocks (not Tesla) he believes will soar from this $7 trillion shift.
📊 Pre-Market Movers
AstraZeneca (AZN) is drawing pre-market attention after inking an exclusive global license agreement with China's Dizal Pharmaceutical for Zegfrovy, a lung cancer treatment, in a deal valued at up to $1.5 billion. Deals of this size in oncology tend to move the needle not just for AZN but for sector peers, so watch the broader pharma and biotech ETFs for early directional clues.On the auto side, BMW (BMWYY) is facing a recall of over 29,000 U.S. vehicles due to fire risk linked to engine starter relay corrosion, and Subaru's parent Fuji Heavy (FUJHY) is recalling more than 541,000 vehicles over incorrect certification labels. Neither recall is catastrophic on its own, but recalls carry reputational and cost implications that can weigh on shares at the margin.
The New York Times (NYT) is also in focus after its journalists were subpoenaed to testify before a federal grand jury in a leak probe tied to reporting on President Trump. That's an unusual legal and First Amendment story for a publicly traded media company, and it may attract some speculative trading interest in NYT shares early in the session.
🔍 Today's Watchlist
- AZN: AstraZeneca's $1.5B Zegfrovy licensing deal puts the stock and lung cancer treatment pipeline names in focus all session.
- GOOG, GOOGL: Swiss antitrust probe into Android default search adds to global regulatory pressure on Alphabet heading into the open.
- IVBIY: Innovent Biologics' $1.1B licensing deal with Spero could spark interest across China-based biotech names today.
- 10-Year Treasury at 4.61%: Watch how rising yields interact with Nasdaq strength as the session progresses.
- SSNLF: Samsung's ADR exploration is early-stage but could be a catalyst for semiconductor sector sentiment throughout the day.
The 2026 Elon Crash
Every bank in America is now facing an imminent crisis. One that could see trillions of dollars rush out of the traditional financial sector… and into a new store of wealth. Ultimately, this could trigger a collapse of the entire banking system. The catalyst isn't the war in Iran, rate cuts, or pumped-up AI stocks… It's Elon Musk. This has to do with a new project he's just launched that almost no one is talking about (except this one banking insider). It's a direct threat to every bank in America, including yours.
🎯 The Morning Playbook
The setup today is a tale of two markets. Nasdaq-heavy growth and tech names have tailwinds from futures momentum, but rising yields and scattered regulatory headlines are the speed bumps to watch. The smart play is to stay nimble and not chase the open aggressively until you see how the bond market behaves in the first hour.Biotech and pharma look like the most actionable sector this morning, with AZN and the Spero-Innovent deal giving the group a reason to attract fresh capital. If you have exposure there, today is a monitoring day more than an action day, watching for confirmation that deal enthusiasm holds up post-open.
Zoom out for a second and note that Samsung's potential ADR listing, Shein's Hong Kong IPO approval, and Iran's defiant oil export comments are all reminders that global capital markets are getting more interconnected and more complicated by the week. Stay informed, stay flexible, and let the first 30 minutes of trading tell you more than any pre-market headline can.
🔍 Hand-Picked for You
A breakthrough tech backed by Elon Musk, Sam Altman, and Nvidia CEO Jensen Huang could soon be worth more than the stocks of Apple, Microsoft, and Amazon—combined. It's likely the only answer to a $33 trillion problem... but most people don't yet know it exists. A man who has consulted for the Penta...
Click here to see this tech with your own eyes—and learn how you could invest in the companies that own it.
Biden's smell hadn't even left the Oval Office yet… And Trump got to work immediately on the most secretive government operation since the Manhattan Project. While the world was distracted by tariffs, Trump redacted over 750 government files. Because Trump saw the writing on the wall: These files we...
Click here to see what's inside the "Redacted Trump Files" before the world finds out the shocking truth.
For years, we've been told SpaceX is a rocket company. But according to new satellite images from 300 miles above the Earth's surface, there is something very strange going on at SpaceX right now that has nothing to do with space. It could soon replace our need for foreign oil forever and ignite a $...
Click here to learn more.
Not every market move can wait. Our text alerts deliver the ones that can't. One short alert, straight to your phone, when something is worth seeing now. No fluff. No noise. No charge.
Text Me the Alerts